Volume 9 Supplement 1

VII Madrid Breast Cancer Conference: Changes in the treatment of breast cancer

Open Access

Current status of adjuvant endocrine therapy for premenopausal patients with primary breast cancer

  • A Howell1
Breast Cancer Research20079(Suppl 1):S12

https://doi.org/10.1186/bcr1695

Received: 23 May 2007

Published: 19 June 2007

The increased risk of death from cancer in young women attests to its aggressive nature and a greater likelihood of being oestrogen receptor (ER)-negative. Approximately 60% of tumours are ER-positive, however, and thus endocrine therapy is an important consideration in this group. In some countries chemotherapy alone was used for many years until the importance of the additional therapeutic effect of amenorrhea became evident and later, after much scepticism, tamoxifen was shown to be effective in this group of women. Sadly this rather staccato history of treatment has left many questions concerning endocrine therapy in young women unanswered. For example, there have been at least nine studies that show ovarian suppression is equivalent for disease-free and overall survival to chemotherapy, showing equivalent therapeutic advantage. However, the correct design of their studies should have included a third arm of chemotherapy and ovarian ablation and some randomisation to investigate the role of additional tamoxifen. New trials such as SOFT, TEXT and PROMISE will help answer the question of optimal endocrine therapy ± chemotherapy in young women and will also help decide whether aromatase inhibitors are effective in the presence of ovarian suppression. Two further points are important to consider. One is that chemotherapy used alone in very young women with ER-positive disease is detrimental since they do not have chemotherapy-induced amenorrhoea. Secondly, the value of chemotherapy in strongly ER-positive disease is being increasingly questioned.

Authors’ Affiliations

(1)
CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Foundation Trust

References

  1. Brown RJ, Davidson NE: Adjuvant hormonal therapy for pre-menopausal women with breast cancer. Semin Oncol. 2006, 33: 657-663. 10.1053/j.seminoncol.2006.08.014.View ArticlePubMedGoogle Scholar
  2. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RSP: International Breast cancer Study Group: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node positive breast cancer. J Clin Oncol. 2006, 24: 1332-1341. 10.1200/JCO.2005.03.0783.View ArticlePubMedGoogle Scholar
  3. Goldstein LJ: Controversies in adjuvant endocrine treatment of premenopausal women. Clin Breast Cancer. 2006, 6: S36-S40.View ArticlePubMedGoogle Scholar
  4. Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W, Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists Group: Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node positive breast cancer. Eur J Cancer. 2003, 39: 1711-1717. 10.1016/S0959-8049(03)00392-7.View ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2007

Advertisement